Results from a completed phase 2 trial of the experimental therapy NP001 in people with amyotrophic lateral sclerosis (ALS) show that in some trial participants, the drug appeared to be effective at slowing or stopping progression of the disease.
Jim received a bachelor’s degree in art from Greenville College (Ill.). He was the art director at Regular Baptist Press in Schaumburg, Ill., prior to his retirement. Although Jim painted for many years, he is no longer able to hold a paintbrush and work on canvases. This piece was drawn using Photoshop CS3 from a photograph of the original barn. He has illustrated many barns and is now drawing houses using the computer.
Don Cleveland, a longtime MDA research grantee studying amyotrophic lateral sclerosis (ALS), has been elected to the Institute of Medicine (IOM). Election to the IOM is one of the highest honors in the fields of health and medicine, and recognizes individuals who have demonstrated outstanding professional achievement and commitment to science.
Results from a completed phase 1 trial of neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that the stem cells and the surgical method used to transplant them were safe and well-tolerated. In addition, the experimental therapy appears to have "interrupted the progression of the disease" in some trial participants.
The most visible symptom in amyotrophic lateral sclerosis (ALS) is progressive weakness and loss of muscle control due to the loss of nerve cells called motor neurons. But approximately half of all people with ALS also exhibit some symptoms of cognitive impairment and associated behavioral symptoms (frontotemporal dementia, or FTD) at some stage of their disease.